• Biodexa held a general meeting earlier today, passing all resolutions put to shareholders.
• Share capital reorganization was adopted, cutting ordinary shares outstanding by a factor of 10,000 while keeping par value at GBP 0.000001.
• The ordinary share-to-ADS ratio change was also adopted, shifting to 50:1 from 500,000:1.
• Execution is scheduled for July 30, 2026; proportional ownership is expected to remain unchanged, subject to fractional entitlements.
• Directors received authority to allot ordinary shares on a non-pre-emptive basis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-26-009162), on July 29, 2026, and is solely responsible for the information contained therein.